ClinicalTrials.gg

Program

tivoxavir marboxil

Its studies are mostly in Influenza, Human, led by Traws Pharma.

Furthest: phase 2, since Aug 4, 20254 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Traws Pharma43 open or runningphase 2since Aug 4, 2025Dec 16, 2024Nov 2026phase 2 · NCT07503405

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2024First study: phase 1 study in Healthy Volunteer StudyFirst studyNCT06757738 · 66 enrolled · Australia
  2. Aug 4, 2025Phase 2 study in Influenza, HumanNCT07371650 · 105 enrolled · Australia
  3. Mar 25, 2026Phase 2 study in Influenza, HumanNCT07503405 · 165 planned · United Kingdom
  4. Apr 6, 2026Phase 1 study in Influenza, HumanNCT07526506 · 32 planned · Australia

Ahead

  1. Nov 2026Primary completion: phase 2 study in Influenza, HumanNCT07503405
  2. Dec 2026Primary completion: phase 2 study in Influenza, HumanNCT07371650

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07526506Influenza, Human · Australia1RecruitingSep 202632
NCT07503405Influenza, Human · United Kingdom2Not yet recruitingNov 2026165
NCT07371650Influenza, Human · Australia2Active, not recruitingDec 2026105
NCT06757738Healthy Volunteer Study · Australia1CompletedJan 16, 202566

How it is read

Names in the registry

  • “TRX-100”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.